1st June 2023
Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous Urticaria
1st February 2023
Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
1st December 2022
Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria
1st December 2022
Mast cell reduction does not impair human cutaneous wound healing
1st July 2022
Effects of Multiple Dose Treatment with an Anti-KIT Antibody, CDX-0159, in Chronic Spontaneous Urticaria
4th February 2022
Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study
1st February 2022